We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-5.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.54B
AUM Growth
-$303M
Cap. Flow
-$71.8M
Cap. Flow %
-2.82%
Top 10 Hldgs %
38.38%
Holding
180
New
5
Increased
27
Reduced
36
Closed
3

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14M
2
ISRG icon
Intuitive Surgical
ISRG
+$11.4M
3
BSX icon
Boston Scientific
BSX
+$9.19M
4
AZN icon
AstraZeneca
AZN
+$8.8M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.52M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$19.5M
2
MCK icon
McKesson
MCK
+$14.5M
3
MDT icon
Medtronic
MDT
+$11M
4
LLY icon
Eli Lilly
LLY
+$10.6M
5
ILMN icon
Illumina
ILMN
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
2 Real Estate 3.13%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
101
Arcutis Biotherapeutics
ARQT
$3.36B
$3.17M 0.12%
148,874
+17,241
+13% +$354K
VRNA
102
DELISTED
Verona Pharma
VRNA
$3.15M 0.12%
751,905
– –
NTLA icon
103
Intellia Therapeutics
NTLA
$1.49B
$3.01M 0.12%
58,180
– –
BCRX icon
104
BioCryst Pharmaceuticals
BCRX
$2.28B
$2.94M 0.12%
277,434
+80,809
+41% +$834K
HR
105
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.83M 0.11%
104,024
– –
ADPT icon
106
Adaptive Biotechnologies
ADPT
$3.59B
$2.73M 0.11%
337,722
– –
RARE icon
107
Ultragenyx Pharmaceutical
RARE
$2.45B
$2.65M 0.1%
44,365
-96,361
-68% -$5.93M
CERE
108
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$2.33M 0.09%
88,173
+14,492
+20% +$411K
MRUS
109
DELISTED
Merus
MRUS
$2.16M 0.08%
95,290
– –
GTHX
110
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.09M 0.08%
423,869
– –
PRGO icon
111
Perrigo
PRGO
$1.4B
$2.08M 0.08%
51,224
– –
HR icon
112
Healthcare Realty
HR
$7.28B
$1.97M 0.08%
70,662
– –
XRN
113
Chiron Real Estate Inc
XRN
$514M
$1.96M 0.08%
34,979
– –
HOLX
114
DELISTED
Hologic
HOLX
$1.96M 0.08%
28,347
– –
CCXI
115
DELISTED
ChemoCentryx, Inc.
CCXI
$1.94M 0.08%
78,197
– –
NBP
116
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$1.84M 0.07%
162,580
– –
MREO
117
Mereo BioPharma
MREO
$54.7M
$1.74M 0.07%
1,551,082
– –
PYXS icon
118
Pyxis Oncology
PYXS
$168M
$1.69M 0.07%
708,303
– –
AUPH icon
119
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.63M 0.06%
162,599
– –
AFMD
120
DELISTED
Affimed
AFMD
$1.62M 0.06%
58,604
– –
DSGN icon
121
Design Therapeutics
DSGN
$761M
$1.52M 0.06%
108,414
+43,063
+66% +$582K
ZLAB icon
122
Zai Lab
ZLAB
$2.06B
$1.5M 0.06%
43,300
– –
TAK icon
123
Takeda Pharmaceutical
TAK
$54.6B
$1.48M 0.06%
105,073
-105,073
-50% -$1.5M
MEDP icon
124
Medpace
MEDP
$16.1B
$1.41M 0.06%
9,435
– –
RXDX
125
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$1.39M 0.05%
49,195
+27,080
+122% +$785K
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Tekla Capital Management held 180 positions worth $2.54B, down 11% from $2.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 4.4%. Tekla Capital Management opened 5 new positions and exited 3, leaving the 180-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2022 buy was Lantheus: 127,092 shares worth $8.39M.
  • Tekla Capital Management added most to Vertex Pharmaceuticals in Q2 2022, an estimated $14M increase.
  • Tekla Capital Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $19.5M.
  • Tekla Capital Management fully exited Revvity in Q2 2022, selling an estimated $5.83M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2022.
  • Tekla Capital Management opened 5 new positions and closed 3 in Q2 2022.
  • Tekla Capital Management's portfolio value fell 11% quarter-over-quarter to $2.54B.

Based on Tekla Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.